Role of Matrix Metalloproteinases and Therapeutic Benefits of Their Inhibition in Spinal Cord Injury

Neurotherapeutics

Volumn 8, Issue 2, 2011, Pages 206-220

  Zhang, Haoqian ^a   Chang, Mayland ^c   Hansen, Christopher N ^d   Basso, D Michele ^d   Noble Haeusslein, Linda J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NOTRE DAME   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

matrix metalloproteinases; neuropathic pain; recovery; Spinal cord injury; therapeutics

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ABT 518; ABT 770; ALENDRONIC ACID; BATIMASTAT; BB 3103; CGS 27023; CIPEMASTAT; CLODRONIC ACID; DOXYCYCLINE; DOXYCYCLINE HYCLATE; FR 255031; GELATINASE INHIBITOR; ILOMASTAT; INCYCLINIDE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; MMI 166; NE 10244; NE 58051; PAMIDRONIC ACID; PRINOMASTAT; REBIMASTAT; RO 282653; RO 323555; RXP 03; SC 78080; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TOLYLSAM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ALLODYNIA; ANGIOGENESIS; APOPTOSIS; ARTHRITIS; BACTERIAL INFECTION; BLOOD SPINAL CORD BARRIER; BLOOD TOXICITY; BONE FRAGILITY; BONE METASTASIS; CELL ADHESION; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPETITIVE INHIBITION; CONTUSION; DRUG BIOAVAILABILITY; DRUG STRUCTURE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GINGIVA DISEASE; HUMAN; INFLAMMATION; INFLAMMATORY CELL; KAPOSI SARCOMA; LEUKOCYTE; METASTASIS; MUSCULOSKELETAL DISEASE; NEOPLASM; NERVE REGENERATION; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; OXIDATIVE STRESS; PERIPHERAL NERVE INJURY; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; ROSACEA; SCAR FORMATION; SIGNAL TRANSDUCTION; SOLID TUMOR; SPINAL CORD INJURY; THROMBOCYTOPENIA; TUMOR GROWTH; UPREGULATION; WOUND HEALING;

ANIMALS; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; NEURALGIA; SPINAL CORD INJURIES;

EID: 79955071242     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13311-011-0038-0     Document Type: Review

References (100)

1. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-233.
2. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6: 931-944.
3. Yong VW, Agrawal SM, Stirling DP. Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 2007; 4: 580-589.
4. Zhang H, Adwanikar H, Werb Z, Noble-Haeusslein LJ. Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. Neuroscientist 2010; 16: 156-170.
5. Noble LJ, Donovan F, Igarashi T, Goussev S, Werb Z. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002; 22: 7526-7535.
6. Yu F, Kamada H, Niizuma K, Endo H, Chan PH. Induction of mmp-9 expression and endothelial injury by oxidative stress after spinal cord injury. J Neurotrauma 2008; 25: 184-195.
7. Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008; 8: 82-89.
8. Agrawal SM, Lau L, Yong VW. MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 2008; 19: 42-51.
9. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
10. Imai K, Yokohama Y, Nakanishi I, et al. Matrix metalloproteinase 7 [matrilysin] from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995; 270: 6691-6697.
11. Knauper V, Bailey L, Worley JR, Soloway P, Patterson ML, Murphy G. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett 2002; 532: 127-130.
12. Cowell S, Knauper V, Stewart ML, et al. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J 1998; 331(pt 2): 453-458.
13. Crocker SJ, Pagenstecher A, Campbell IL. The TIMPs tango with MMPs and more in the central nervous system. J Neurosci Res 2004; 75: 1-11.
14. de Castro RC Jr., Burns CL, McAdoo DJ, Romanic AM. Metalloproteinase increases in the injured rat spinal cord. Neuroreport 2000; 11: 3551-3554.
15. Duchossoy Y, Horvat JC, Stettler O. MMP-related gelatinase activity is strongly induced in scar tissue of injured adult spinal cord and forms pathways for ingrowing neurites. Mol Cell Neurosci 2001; 17: 945-956.
16. Goussev S, Hsu JY, Lin Y, et al. Differential temporal expression of matrix metalloproteinases after spinal cord injury: relationship to revascularization and wound healing. J Neurosurg 2003; 99: 188-197.
17. Hsu JY, McKeon R, Goussev S, et al. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J Neurosci 2006; 26: 9841-9850.
18. Xu J, Kim GM, Ahmed SH, Yan P, Xu XM, Hsu CY. Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. J Neurosci 2001; 21: 92-97.
19. Wells JE, Rice TK, Nuttall RK, et al. An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. J Neurosci 2003; 23: 10107-10115.
20. Veeravalli KK, Dasari VR, Tsung AJ, et al. Human umbilical cord blood stem cells upregulate matrix metalloproteinase-2 in rats after spinal cord injury. Neurobiol Dis 2009; 36: 200-212.
21. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697-709.
22. Buhler LA, Samara R, Guzman E, et al. Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis. BMC Neurosci 2009; 10: 17.
23. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724-7732.
24. Caron A, Desrosiers RR, Beliveau R. Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9. Exp Cell Res 2005; 310: 105-116.
25. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 2007; 22: E4.
26. Reijerkerk A, Kooij G, van der Pol SM, Khazen S, Dijkstra CD, de Vries HE. Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells. FASEB J 2006; 20: 2550-2552.
27. Whetstone WD, Hsu JY, Eisenberg M, Werb Z, Noble-Haeusslein LJ. Blood-spinal cord barrier after spinal cord injury: relation to revascularization and wound healing. J Neurosci Res 2003; 74: 227-239.
28. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A 1996; 93: 3942-3946.
29. Haorah J, Ramirez SH, Schall K, Smith D, Pandya R, Persidsky Y. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J Neurochem 2007; 101: 566-576.
30. Alexander JS, Elrod JW. Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 2002; 200: 561-574.
31. Sugawara T, Lewen A, Gasche Y, Yu F, Chan PH. Overexpression of SOD1 protects vulnerable motor neurons after spinal cord injury by attenuating mitochondrial cytochrome c release. FASEB J 2002; 16: 1997-1999.
32. Dang AB, Tay BK, Kim HT, Nauth A, Alfonso-Jaume MA, Lovett DH. Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis. Spine [Phila Pa 1976] 2008; 33: E576-579.
33. Trivedi A, Hsu CY, Lin Y, et al. The effects of acute and extended inhibition of matrix metalloproteinases on demyelination and functional recovery after spinal cord injury. Int J Neuroprotect Neuroregen 2005; 2: 30-38.
34. Pizzi MA, Crowe MJ. Matrix metalloproteinases and proteoglycans in axonal regeneration. Exp Neurol 2007; 204: 496-511.
35. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004; 5: 146-156.
36. Jones LL, Yamaguchi Y, Stallcup WB, Tuszynski MH. NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. J Neurosci 2002; 22: 2792-2803.
37. Bradbury EJ, Moon LD, Popat RJ, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002; 416: 636-640.
38. Hsu JY, Bourguignon LY, Adams CM, et al. Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord. J Neurosci 2008; 28: 13467-13477.
39. Busch SA, Horn KP, Silver DJ, Silver J. Overcoming macrophage-mediated axonal dieback following CNS injury. J Neurosci 2009; 29: 9967-9976.
40. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2: 502-511.
41. Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003; 103: 249-257.
42. Detloff MR, Fisher LC, McGaughy V, Longbrake EE, Popovich PG, Basso DM. Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats. Exp Neurol 2008; 212: 337-347.
43. Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008; 14: 331-336.
44. Kobayashi H, Chattopadhyay S, Kato K, et al. MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage. Mol Cell Neurosci 2008; 39: 619-627.
45. Chattopadhyay S, Myers RR, Janes J, Shubayev V. Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve. Brain Behav Immun 2007; 21: 561-568.
46. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995; 201: 223-226.
47. Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain 2006; 7: S3-S12.
48. Schafers M, Sorkin L. Effect of cytokines on neuronal excitability. Neurosci Lett 2008; 437: 188-193.
49. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006; 6: 227-239.
50. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006; 25: 115-136.
51. Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 2010; 1803: 72-94.
52. Dorman G, Cseh S, Hajdu I, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010; 70: 949-964.
53. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9: 63-79.
54. Wada CK, Holms JH, Curtin ML, et al. Phenoxyphenyl sulfone N-formylhydroxylamines [retrohydroxamates] as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J Med Chem 2002; 45: 219-232.
55. Ishikawa T, Nishigaki F, Miyata S, et al. Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. Br J Pharmacol 2005; 144: 133-143.
56. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258-265.
57. Romero-Perez D, Fricovsky E, Yamasaki KG, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 2008; 52: 1086-1094.
58. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004; 3: 744-751.
59. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009; 196: 168-179.
60. Lee HM, Golub LM, Cao J, et al. CMT-3, a non-antimicrobial tetracycline [TC], inhibits MT1-MMP activity: relevance to cancer. Curr Med Chem 2001; 8: 257-260.
61. Teronen O, Heikkila P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999; 878: 453-465.
62. Heikkila P, Teronen O, Moilanen M, et al. Bisphosphonates inhibit stromelysin-1 [MMP-3], matrix metalloelastase [MMP-12], collagenase-3 [MMP-13] and enamelysin [MMP-20], but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002; 13: 245-254.
63. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949-2954.
64. Hoffman A, Qadri B, Frant J, et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem 2008; 51: 1406-1414.
65. Matziari M, Beau F, Cuniasse P, Dive V, Yiotakis A. Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. J Med Chem 2004; 47: 325-336.
66. Reiter LA, Mitchell PG, Martinelli GJ, Lopresti-Morrow LL, Yocum SA, Eskra JD. Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorg Med Chem Lett 2003; 13: 2331-2336.
67. Brown S, Bernardo MM, Li ZH, et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 2000; 122: 6799-6800.
68. Toth M, Bernardo MM, Gervasi DC, et al. Tissue inhibitor of metalloproteinase [TIMP]-2 acts synergistically with synthetic matrix metalloproteinase [MMP] inhibitors but not with TIMP-4 to enhance the [membrane type 1]-MMP-dependent activation of pro-MMP-2. J Biol Chem 2000; 275: 41415-41423.
69. Forbes C, Shi Q, Fisher JF, et al. Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases. Chem Biol Drug Des 2009; 74: 527-534.
70. Gu Z, Cui J, Brown S, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005; 25: 6401-6408.
71. Luplertlop N, Misse D, Bray D, et al. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep 2006; 7: 1176-1181.
72. Ota R, Kurihara C, Tsou TL, et al. Roles of matrix metalloproteinases in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab 2009; 29: 1547-1558.
73. Guo Z, Sun X, He Z, Jiang Y, Zhang X, Zhang JH. Matrix metalloproteinase-9 potentiates early brain injury after subarachnoid hemorrhage. Neurol Res 2010; 32: 715-720.
74. He ZJ, Huang ZT, Chen XT, Zou ZJ. Effects of matrix metalloproteinase 9 inhibition on the blood brain barrier and inflammation in rats following cardiopulmonary resuscitation. Chin Med J [Engl] 2009; 122: 2346-2351.
75. Lee M, Villegas-Estrada A, Celenza G, et al. Metabolism of a highly selective gelatinase inhibitor generates active metabolite. Chem Biol Drug Des 2007; 70: 371-382.
76. Lee M, Celenza G, Boggess B, et al. A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition. Chem Biol Drug Des 2009; 73: 189-202.
77. Testero SA, Lee M, Staran R, et al. Sulfonate-containing thiiranes as selective gelatinase inhibitors. Med Chem Lett 2011; 2: 177-181.
78. Ikejiri M, Bernardo MM, Meroueh SO, et al. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 2005; 70: 5709-5712.
79. Gooyit M, Lee M, Hesek D, et al. Synthesis, kinetic characterization and metabolism of diastereomeric 2-[1-[4-phenoxyphenylsulfonyl]ethyl]thiiranes as potent gelatinase and MT1-MMP inhibitors. Chem Biol Drug Des 2009; 74: 535-546.
80. Botos I, Scapozza L, Zhang D, Liotta LA, Meyer EF. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A 1996; 93: 2749-2754.
81. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 1992; 31: 7152-7154.
82. Naglich JG, Jure-Kunkel M, Gupta E, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001; 61: 8480-8485.
83. Gatto C, Rieppi M, Borsotti P, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999; 5: 3603-3607.
84. Aranapakam V, Grosu GT, Davis JM, et al. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem 2003; 46: 2361-2375.
85. Tamura Y, Watanabe F, Nakatani T, et al. Highly selective and orally active inhibitors of type IV collagenase [MMP-9 and MMP-2]: N-sulfonylamino acid derivatives. J Med Chem 1998; 41: 640-649.
86. Aoki T, Kataoka H, Morimoto M, Nozaki K, Hashimoto N. Macrophage-derived matrix metalloproteinase-2 and -9 promote the progression of cerebral aneurysms in rats. Stroke 2007; 38: 162-169.
87. Becker DP, Barta TE, Bedell LJ, et al. Orally active MMP-1 sparing alpha-tetrahydropyranyl and alpha-piperidinyl sulfone matrix metalloproteinase [MMP] inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. J Med Chem 2010; 53: 6653-6680.
88. Kolodziej SA, Hockerman SL, Boehm TL, et al. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates. Bioorg Med Chem Lett 2010; 20: 3557-3560.
89. Nelson FC, Delos Santos E, Levin JI, et al. Benzodiazepine inhibitors of the MMPs and TACE. Bioorg Med Chem Lett 2002; 12: 2867-2870.
90. Yang SM, Scannevin RH, Wang B, et al. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents. Bioorg Med Chem Lett 2008; 18: 1140-1145.
91. Curtin ML, Florjancic AS, Heyman HR, et al. Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770. Bioorg Med Chem Lett 2001; 11: 1557-1560.
92. Chung YJ, Lee KH, Park SH, Cho CW, Han MS. 5-carboxylate substituted piperazine-2-ones as potent and selective MMP-2 inhibitors. Bull Korean Chem Soc 2008; 29: 1103-1104.
93. Maquoi E, Sounni NE, Devy L, et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2, 4, 6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 2004; 10: 4038-4047.
94. Kim SH, Pudzianowski AT, Leavitt KJ, et al. Structure-based design of potent and selective inhibitors of collagenase-3 [MMP-13]. Bioorg Med Chem Lett 2005; 15: 1101-1106.
95. Levin JI, Du MT, DiJoseph JF, et al. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. Bioorg Med Chem Lett 2001; 11: 235-238.
96. Levin JI, Gu Y, Nelson FC, et al. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett 2001; 11: 239-242.
97. Zhang L, Zhang J, Fang H, Wang Q, Xu W. Design, synthesis and preliminary evaluation of new cinnamoyl pyrrolidine derivatives as potent gelatinase inhibitors. Bioorg Med Chem 2006; 14: 8286-8294.
98. Cheng XC, Wang Q, Fang H, Tang W, Xu WF. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Bioorg Med Chem 2008; 16: 5398-5404.
99. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog [COL-3] in a metastatic prostate cancer model. Int J Cancer 2002; 98: 297-309.
100. Lee M, Bernardo MM, Meroueh SO, Brown S, Fridman R, Mobashery S. Synthesis of chiral 2-[4-phenoxyphenylsulfonylmethyl]thiiranes as selective gelatinase inhibitors. Org Lett 2005; 7: 4463-4465.